|Type||Public (Bolsa española - ALM)|
|Headquarters||General Mitre, 151 08022 Barcelona, Spain|
|Products||Aceclofenac (Airtal and other trademarks)*
Almagate (Almax and other trademarks)*
Candesartan cilexetil (Parapres)
Ebastine (Ebastel and other trademarks)*
Fluprednidene (Decoderm Tri and other trademarks)
Sitagliptin + metformin (Efficib)
Sodium diclofenac + hyaluronic
Soya oil (Balneum and other trademarks)
|Revenue||1,002€ million (2010)|
|This article relies on references to primary sources. (September 2007)|
||This article appears to be written like an advertisement. (May 2014)|
Almirall, S.A. (formerly Almirall Prodesfarma S.A.), usually referred to simply as Almirall (BMAD: ALM), is a Spanish international pharmaceutical company. The company is headquartered in Barcelona, Spain and was the largest (by sales and employees) Spanish pharmaceutical company in 2004. It has affiliates in Austria, Belgium, France, Germany, Italy, Mexico, Nordic countries, Poland, Portugal, Switzerland and UK - Ireland.
- 1 Summary
- 2 History
- 3 The company today
- 4 Almirall medicines
- 5 Research and development
- 6 References
- 7 Turnover statistics
- 8 Proprietary products
- 9 References and notes
- 10 External links
Almirall, an international, innovation-based pharmaceutical company whose headquarters are in Barcelona (Spain), researches, develops, produces and commercializes proprietary, R&D medicines and those under licence.
Almirall was founded in 1943 in Barcelona (Spain) and began its research and development activities in the 1960s. It has evolved to become a prominent pharmaceutical company within the current European panorama. One of its achievements was to become a stock market listed company in June 2007.
Almirall has 12 affiliates (including Spain) in Europe and Latin America, 3 R&D centres and 2 unit centres, 5 production centres and an overall workforce of around 2,850 professionals, of whom around 523 work in R&D.
The company opened its first headquarters in a building of 50 m2 located in Martínez de la Rosa street in the Gracia area of Barcelona.
It was founded by Antonio Gallardo Carrera, with support from a small team of people. He created a small laboratory during the period when the country was suffering the aftermath of the Spanish Civil War and while the rest of Europe was immersed in World War II. The first products were launched against this backdrop: an anthelmintic (Lombrikal), a parasiticide (Tundra) and a gynaecological antiseptic known as Leucosine. Other products manufactured by Almirall at the time include an anti-flu medicine (Gripex) and the first balsam rectal treatment launched on the Spanish market (Rectopulmo) and which maintained a strong presence for over forty years.
In the spring of 1961, the laboratory was extended and by that stage it included a research department. Almirall launched a significant number of its own research antibiotics and balms. However, it was 1970 when its real policy for discovery and development of medicines got underway. It was then that the first Almirall proprietary research product was launched; an antibiotic (Sevilmine).
Work carried out during the 1970s developed in the 1980s into the launch of several Almirall R&D drugs and the obtaining of patents in countries such as the United States, Japan, Germany, the United Kingdom, the Netherlands and South Korea.
Antonio and Jorge Gallardo Ballart, sons of Antonio Gallardo Carrera, took on the responsibility left by their father on his death in 1988. They decided to merge Almirall with Prodesfarma in 1997, seeking an opportunity for growth. Then Jorge Gallardo took the reins of the company being, at present, Chairman-Chief Executive Officer of Almirall.
In June 2007, Almirall was listed on the stock market. It then acquired Hermal, a German company specialised in dermatology and a portfolio of eight products from Shire, whose main products also belong to the said therapeutic area.
The company today
Almirall is the 69 highest turnover pharmaceutical company in the world and ranks 32 in Europe. Its medicines are present in over 70 countries in the five continents. Almirall holds a leadership position in the Spanish pharmaceutical sector, with a market share of 5% (IMS TAM Dec.10).
One of Almirall’s most notable features is its commitment to R&D. In 2010, resources allocated to R&D totalled 145 million euros; over 15% of net sales. In terms of workforce, over 15% of its professionals work in R&D.
In July 2014 the company entered into a deal with AstraZeneca to sell its subsidiary Almirall Sofotec and its lung treatments including the COPD drug Eklira. The $2.1 billion deal included an allocation of $1.2 billion for development in the respiratory franchise, one of AstraZeneca's main growth platforms.
Almirall medicines are present in over 70 countries in the five continents and represent around 45% of total income in 2010.
Almirall R&D medicines are: almotriptan (Almogran, antimigraine - 2000), aceclofenac (Airtal and other trademarks, anti-inflammatory - 1992), ebastine (Ebastel and other trademarks, antihistamine - 1990), cinitapride (Cidine, gastroprokinetic - 1990), piketoprofen (Calmatel, anti-inflammatory - 1985), almagate (Almax, antacid - 1984) and clebopride (Cleboril, gastroprokinetic - 1979).
In the dermatology area, other products include Vaniqa (eflornithine) for facial hirsutism, and Solaraze (diclofenac sodium + hyaluronic acid) for actinic keratoses, Balmeum (Soya oil) for Atopic dermatitis and Decoderm Tri (Fluprednidene) for mycotic dermatitis.
Almirall’s affiliates are in:
• Nordic countries
• United Kingdom-Ireland
Top 15 medicines
Around 73% of sales in 2010 correspond to Almirall’s fifteen highest selling products, of which four are proprietary research and development products:
|Brand||Active ingredient||Therapeutic area||Pathology|
|1||Ebastel and others||Ebastine*||Respiratory||Allergy|
|3||Esertia||Escitalopram||Central nervous system||Depression|
|4||Plusvent||Salmeterol+fluticasone||Respiratory||Asthma & COPD|
|5||Almogran and others||Almotriptan*||Central nervous system||Migraine|
|7||Airtal and others||Aceclofenac*||Osteomuscular||Pain|
|9||Dobupal||Venlafaxine||Central nervous system||Depression|
|10||Tesavel & Efficib||Sitagliptin & sitagliptin + metformin||Gastrointestinal||Diabetes|
|11||Solaraze||Diclofenac solium + hyaluronic||Dermatology||Actinic keratoses|
|12||Almax and others||Almagate*||Gastrointestinal||Antacid|
|13||Balneum and others||Soya oil||Dermatology||Atopic dermatitis|
|15||Decoderm Tri and others||Fluprednidene||Dermatology||Mycotic dermatitis|
- (*)Almirall R&D products
Sales per therapeutic areas
|Therapeutic areas||In the world 2010 (1)|
|Central nervous system||18.5 %|
|Osteomuscular system||7.3 %|
Source: (1) Annual accounts 2010 (Registro Mercantil de Barcelona and CNMV)
Almirall has obtained seven new medicines from around 20,000 compounds synthesised. Almirall R&D medicines are:
- Almotriptan, for treatment of migraine. This molecule received approval from the U.S. Food and Drug Administration (FDA), the maximum health authority in North America. It was the first time that a Spanish R&D medicine has been granted approval from the FDA.
- Aceclofenac, indicated for muscular inflammations and arthritis. Aceclofenac stick was launched in 2007: a new pocket- sized format against pain and inflammation. It was the first Spanish research medicine registered in the United Kingdom.
- Ebastine, anti-histamine for the treatment of allergies. In 2005 ebastine presented its new galenic formulation Flas, a fast mouth-dissolving formula that was an innovation in the anti-histamine market.
- Cintapride, a gastroprokinetic to stimulate gastrointestinal motility.
- Piketoprofen, a topical anti-inflammatory.
- Almagate, indicated for gastric acidity which has become the antacid of reference in the Spanish market. In 2005 the new Almax Masticable 1g - soft chewable tablet was presented in Spain. This is a galenic formulation with a minty taste that does not leave residue in the mouth.
- Clebopride, a gastroprokinetic to improve gastrointestinal motility, which was the first Spanish active ingredient licensed in Japan.
Research and development
Almirall’s R&D strategy is based on creating research teams focussed on specific therapeutic targets. The areas on which it focuses research are related to the treatment of asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal disorders, psoriasis and other dermatologic conditions.
Almirall scientists have established a network of external collaborators in biology, chemistry and X-ray crystallography to help generate research programmes and access new technologies that may enable new research programmes to be generated and access to new technologies that may enable new drug- seeking processes to be speeded up. This network includes collaborations with universities, research centres and technology companies in Europe and the USA. Almirall also encourages the emergency of local biotechnology companies. Examples of this is the prominent role of Almirall in the Genius Pharma project, a technological platform as well as Neogenius, a programme for the discovery and development of new painkilling medicines form patiens suffering from osteoarthritis, sponsored by the Spanish government.
In 2008, Almirall incorporated into the Innovative Medicines Initiative (IMI), a joint project between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA, the European management of the pharmaceutical industry) to increase R&D in the pharmaceutical sector on a European level.
To fully develop its R&D work, Almirall has infrastructures such as the R&D centre in Sant Feliu de Llobregat (Barcelona) inaugurated in 2006. By housing the majority of the Almirall R&D structure under one roof, synergies can be fully exploited. Almirall also has two R&D units in the Barcelona area: Chemical Synthesis and Active ingredient scaling-up (it implies modifying the obtaining of a few grams of substance in the laboratory to adapt it to industrial equipment able to produce product quantities of tens or hundreds of kilograms).
Moreover, Almirall also has a centre of excellence for inhalation technology, located in Bad Homburg (near Frankfurt, Germany), and made up of a team of technical experts in pharmaceutical innovation for the administration of medicinal products by inhalation. From here Almirall has patented a multiple dose dry powder inhaler (Genuair).
As a result of its acquisition of Hermal in August 2007, Almirall also has a team located in Reinbek (Germany) that focuses on dermatology R&D: the center of excellence in dermatology.
Almirall has five production centres: three pharmaceutical plants (two in Spain and one in Germany) and two chemical plants (in the Barcelona area). The facilities adhere to international manufacturing standards. In 2010, production rounded 100 million pharmaceutical units and exceeded a volume of 125 tonnes in chemical plants.
Almirall received the TÜV Rheinland certificate in March 2007, endorsing the conformity of its System for Risk Prevention Management with the international standard OHSAS 18001, and recognising that its criteria for health and safety in the workplace are higher than the standards of the legislation in force in Spain. Moreover, the Almirall fine chemistry business unit (Ranke Química, S.L.) was recognised in 2008 for its low accident rate by the Autonomous Commission for Safety and Hygiene at work in the Chemical and Related Industries (COASHIQ).
- Annual report 2010
- Book Almirall 50 years of pharmaceutical research
- Web: www.almirall.com
- Press dossier
- Annual accounts 2010
- Press releases
- Company triptych
- Turnover 2004: €700 million (on sales of €956 million)
- Turnover 2005: €736 million
- Turnover 2006: €758 million
- Turnover 2007: €793 million
- Turnover 2008: €903 million
- Turnover 2009: €925,5 million
- Turnover 2010: €882,4 million
Almirall acquired a portfolio of products from both Shire (Solaraze and Vaniqa) and Hermal (Balneum range, Unguentum M and other dermatology products) in December 2007.
Almirall now have a large dermatology sales force in the UK.
products that have been developed by Almirall
- Aceclofenac (NSAID)
- Almagate (antacid)
- Almotriptan (antimigraine drug)
- Clebopride (antiemetic, prokinetic)
- Ebastine (antihistamine)
- Thiomucase anticellulite
References and notes
- O'Neill, Michael F.; McGettigan, Gerard (15 August 2005), Table 1: Data from the five major Spanish pharmaceutical companies, "Spanish biotechnology: anyone for PYMEs?", Drug Discovery Today, News and Comment 10 (16): 1079, doi:10.1016/S1359-6446(05)03549-X, ISSN 1359-6446
- "ALMIRALL SA (ALM:Continuous): Company Description - Businessweek". investing.businessweek.com. Retrieved 28 September 2012.
- "AstraZeneca enters tie-up with Almirall for its portfolio of respiratory drugs". Business Sun. Retrieved 31 July 2014.
- "Evaluation of a new antacid, almagate". Arzneimittelforschung 34 (10A): 1350–4. 1984. PMID 6439224.
-  (Almirall company website)